Direct and biologically significant interactions of human herpesvirus 8 interferon regulatory factor 1 with STAT3 and Janus kinase TYK2.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
09
06
2023
accepted:
07
11
2023
revised:
04
12
2023
medline:
6
12
2023
pubmed:
20
11
2023
entrez:
20
11
2023
Statut:
epublish
Résumé
Human herpesvirus 8 (HHV-8) encodes four viral interferon regulatory factors (vIRFs) that target cellular IRFs and/or other innate-immune and stress signaling regulators and suppress the cellular response to viral infection and replication. For vIRF-1, cellular protein targets include IRFs, p53, p53-activating ATM kinase, BH3-only proteins, and antiviral signaling effectors MAVS and STING; vIRF-1 inhibits each, with demonstrated or likely promotion of HHV-8 de novo infection and productive replication. Here, we identify direct interactions of vIRF-1 with STAT3 and STAT-activating Janus kinase TYK2 (the latter reported previously by us to be inhibited by vIRF-1) and suppression by vIRF-1 of cytokine-induced STAT3 activation. Suppression of active, phosphorylated STAT3 (pSTAT3) by vIRF-1 was evident in transfected cells and vIRF-1 ablation in lytically-reactivated recombinant-HHV-8-infected cells led to increased levels of pSTAT3. Using a panel of vIRF-1 deletion variants, regions of vIRF-1 required for interactions with STAT3 and TYK2 were identified, which enabled correlation of STAT3 signaling inhibition by vIRF-1 with TYK2 binding, independently of STAT3 interaction. A viral mutant expressing vIRF-1 deletion-variant Δ198-222 refractory for TYK2 interaction and pSTAT3 suppression was severely compromised for productive replication. Conversely, expression of phosphatase-resistant, protractedly-active STAT3 led to impaired HHV-8 replication. Cells infected with HHV-8 mutants expressing STAT3-refractory vIRF-1 deletion variants or depleted of STAT3 displayed reduced vIRF-1 expression, while custom-peptide-promoted STAT3 interaction could effect increased vIRF-1 expression and enhanced virus replication. Taken together, our data identify vIRF-1 targeting and inhibition of TYK2 as a mechanism of STAT3-signaling suppression and critical for HHV-8 productive replication, the importance of specific pSTAT3 levels for replication, positive roles of STAT3 and vIRF-1-STAT3 interaction in vIRF-1 expression, and significant contributions to lytic replication of STAT3 targeting by vIRF-1.
Identifiants
pubmed: 37983265
doi: 10.1371/journal.ppat.1011806
pii: PPATHOGENS-D-23-00945
pmc: PMC10695398
doi:
Substances chimiques
viral interferon regulatory factors
0
Interferon Regulatory Factor-1
0
Janus Kinases
EC 2.7.10.2
Tumor Suppressor Protein p53
0
TYK2 protein, human
EC 2.7.10.2
TYK2 Kinase
EC 2.7.10.2
STAT3 protein, human
0
STAT3 Transcription Factor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1011806Subventions
Organisme : NIAID NIH HHS
ID : R01 AI140855
Pays : United States
Informations de copyright
Copyright: © 2023 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2013;8(3):e59591
pubmed: 23555719
Nat Commun. 2019 Jul 19;10(1):3203
pubmed: 31324791
Methods Mol Biol. 2010;634:421-30
pubmed: 20677001
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9599-604
pubmed: 11481452
J Virol. 2012 Sep;86(18):9708-20
pubmed: 22740391
J Virol. 2007 Mar;81(5):2449-58
pubmed: 17151100
J Virol. 2018 Mar 14;92(7):
pubmed: 29343584
J Virol. 2004 Jun;78(12):6621-35
pubmed: 15163753
J Biol Chem. 2009 Aug 28;284(35):23272-85
pubmed: 19553679
Biotechniques. 2006 Feb;40(2):191-7
pubmed: 16526409
J Biol Chem. 1997 Aug 1;272(31):19625-31
pubmed: 9235971
Oncogene. 2000 May 15;19(21):2474-88
pubmed: 10851046
J Virol. 2007 Aug;81(15):8282-92
pubmed: 17522209
Nat Rev Immunol. 2012 Jan 06;12(2):125-35
pubmed: 22222875
J Virol. 2007 Nov;81(22):12680-4
pubmed: 17855527
J Virol. 2001 Mar;75(5):2345-52
pubmed: 11160738
J Virol Methods. 2011 Jun;174(1-2):12-21
pubmed: 21419799
Hepatology. 2013 Nov;58(5):1558-68
pubmed: 23703790
Mol Cell Biol. 2001 Nov;21(22):7721-30
pubmed: 11604508
N Engl J Med. 2012 May 17;366(20):1905-13
pubmed: 22591296
J Virol. 2015 Oct 28;90(1):506-20
pubmed: 26512076
J Virol. 2020 Jan 6;94(2):
pubmed: 31666375
Biochemistry. 2006 May 2;45(17):5599-605
pubmed: 16634641
J Virol. 2001 Jan;75(1):429-38
pubmed: 11119611
Science. 1996 Dec 6;274(5293):1739-44
pubmed: 8939871
J Virol. 2006 Dec;80(23):11638-50
pubmed: 16987978
Blood. 2003 Feb 15;101(4):1535-42
pubmed: 12393476
Sci Rep. 2015 Dec 03;5:17663
pubmed: 26631279
J Biol Chem. 2006 Nov 3;281(44):33172-81
pubmed: 16956893
J Gen Virol. 2003 Jun;84(Pt 6):1471-1483
pubmed: 12771416
J Virol. 1999 Oct;73(10):8268-78
pubmed: 10482577
Oncogene. 1997 Oct 16;15(16):1979-85
pubmed: 9365244
J Virol. 1998 Jul;72(7):5433-40
pubmed: 9620998
Cytotechnology. 2010 Jan;62(1):73-82
pubmed: 20309632
Curr Opin HIV AIDS. 2017 Jan;12(1):47-56
pubmed: 27662501
Oncogene. 1999 Oct 14;18(42):5727-37
pubmed: 10523853
Sci Signal. 2010 Aug 03;3(133):ra58
pubmed: 20682912
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):600-5
pubmed: 22190485
J Exp Med. 2002 Sep 2;196(5):641-53
pubmed: 12208879
Mol Cell Biol. 1999 Feb;19(2):1401-9
pubmed: 9891073
J Virol. 2014 Oct;88(20):12167-72
pubmed: 25078695
PLoS Pathog. 2022 Jul 1;18(7):e1010676
pubmed: 35776779
PLoS Pathog. 2019 May 6;15(5):e1007743
pubmed: 31059555
J Virol. 2013 Oct;87(19):10763-76
pubmed: 23903834
Front Immunol. 2019 Jun 26;10:1448
pubmed: 31293595
Nat Med. 1997 Mar;3(3):287-92
pubmed: 9055855
J Virol. 2003 Apr;77(7):4205-20
pubmed: 12634378
J Virol. 2002 Mar;76(6):2721-9
pubmed: 11861839
J Exp Med. 2011 Jul 4;208(7):1359-66
pubmed: 21690253
J Virol. 2017 Oct 27;91(22):
pubmed: 28878084
Biol Chem. 2017 Jul 26;398(8):857-870
pubmed: 28455950
J Virol. 2015 Aug;89(15):7979-90
pubmed: 26018151
J Virol. 2020 May 18;94(11):
pubmed: 32213613
PLoS One. 2013;8(2):e57063
pubmed: 23431397
PLoS Pathog. 2010 Aug 05;6(8):e1001031
pubmed: 20700448
Nat Microbiol. 2019 Jun;4(6):914-924
pubmed: 30936491
Biochem Biophys Res Commun. 2017 May 6;486(3):700-705
pubmed: 28342865
J Virol. 2015 Nov;89(22):11347-55
pubmed: 26339061
J Virol. 2009 Jan;83(2):722-33
pubmed: 18987143
J Virol. 2013 Sep;87(17):9398-410
pubmed: 23785197
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4306-15
pubmed: 26199418
Science. 2002 Nov 15;298(5597):1432-5
pubmed: 12434062
PLoS Pathog. 2012;8(6):e1002748
pubmed: 22685405
J Biol Chem. 1998 Sep 25;273(39):25510-5
pubmed: 9738022
J Biol Chem. 2004 Dec 10;279(50):51793-803
pubmed: 15258150
Cancer Res. 2005 Mar 1;65(5):1738-47
pubmed: 15753369
J Virol. 2020 Sep 15;94(19):
pubmed: 32669340
J Gen Virol. 2014 Jan;95(Pt 1):44-51
pubmed: 24158397
Nat Clin Pract Oncol. 2005 Jun;2(6):315-24
pubmed: 16264989
J Biol Chem. 2016 Mar 18;291(12):6281-91
pubmed: 26786098
J Virol. 2013 Oct;87(19):10816-27
pubmed: 23903842